{"id":"F2017L00469","name":"Statement of Principles concerning bronchiectasis (Balance of Probabilities) (No. 31 of 2017)","slug":"statement-of-principles-concerning-bronchiectasis-balance-of-probabilities-no-31-of-2017","collection":"legislative_instrument","jurisdiction":"commonwealth","status":"in_force","isInForce":true,"actNumber":null,"makingDate":null,"administeringDepartment":null,"currentVersion":{"id":439179,"registerId":"F2017L00469-fast-fetch-1775955291662","compilationNumber":null,"startDate":"2026-04-12","status":"InForce","reasons":null,"registeredAt":null},"sections":[{"sectionNumber":"1","sectionType":"section","heading":"Statement of Principles concerning bronchiectasis (Balance of Probabilities) (No. 31 of 2017)","content":"---\nmeta-content-style-type: text/css\nmeta-content-type: application/xhtml+xml; charset=utf-8\nmeta-generator: Aspose.Words for .NET 20.2\n---\n\n?xml version=\"1.0\" encoding=\"utf-8\" standalone=\"no\"?>\n\n\n\n \n\nStatement of Principles\n\nconcerning\n\nBRONCHIECTASIS (Balance of Probabilities)\n\n(No. 31 of 2017)\n\nThe Repatriation Medical Authority determines the following Statement of Principles under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n \n\nDated 21 April 2017\n\n \n\n \n\n \n\n \n\n \n\n| The Common Seal of the Repatriation Medical Authority was affixed to this instrument at the direction of:
|\n| --- |\n| 
Professor Nicholas Saunders AO
Chairperson
|\n\n\n \n\n \n\n\nContents\n\n1 Name\n\n2 Commencement\n\n3 Authority\n\n4 Revocation\n\n5 Application\n\n6 Definitions\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n8 Basis for determining the factors\n\n9 Factors that must exist\n\n10 Relationship to service\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nSchedule 1 - Dictionary\n\n1 Definitions\n\n \n\n\n\n\n1 Name\n\nThis is the Statement of Principles concerning bronchiectasis (Balance of Probabilities) (No. 31 of 2017).\n\n2 Commencement\n\n This instrument commences on 22 May 2017.\n\n3 Authority\n\nThis instrument is made under subsection 196B(3) of the Veterans' Entitlements Act 1986.\n\n4 Revocation\n\nThe Statement of Principles concerning bronchiectasis No. 18 of 2009 made under subsection 196B(3) of the VEA is revoked.\n\n5 Application\n\nThis instrument applies to a claim to which section 120B of the VEA or section 339 of the Military Rehabilitation and Compensation Act 2004 applies.\n\n6 Definitions\n\nThe terms defined in the Schedule 1 - Dictionary have the meaning given when used in this instrument.\n\n7 Kind of injury, disease or death to which this Statement of Principles relates\n\n(1) This Statement of Principles is about bronchiectasis and death from bronchiectasis.\n\nMeaning of bronchiectasis\n\n(2) For the purposes of this Statement of Principles, bronchiectasis means:\n\n(a) an acquired lung disease with permanent and irreversible, abnormal dilatation of bronchi and bronchioles; and\n\n(b) excludes congenital bronchiectasis, and bronchiectasis associated with cystic fibrosis, alpha-1-antitrypsin deficiency, common variable immune deficiency and other genetic disorders.\n\nDeath from bronchiectasis\n\n(3) For the purposes of this Statement of Principles, bronchiectasis, in relation to a person, includes death from a terminal event or condition that was contributed to by the person's bronchiectasis.\n\nNote: terminal event is defined in the Schedule 1 – Dictionary.\n\n8 Basis for determining the factors\n\nOn the sound medical‑scientific evidence available, the Repatriation Medical Authority is of the view that it is more probable than not that bronchiectasis and death from bronchiectasis can be related to relevant service rendered by veterans or members of the Forces under the VEA, or members under the MRCA.\n\nNote: relevant service is defined in the Schedule 1 – Dictionary.\n\n9 Factors that must exist\n\nAt least one of the following factors must exist before it can be said that, on the balance of probabilities, bronchiectasis or death from bronchiectasis is connected with the circumstances of a person's relevant service:\n\n(1) having viral or bacterial pneumonia within the five years before the clinical onset of bronchiectasis;\n\n(2) having pertussis of sufficient severity to require hospitalisation, within the five years before the clinical onset of bronchiectasis;\n\n(3) having pulmonary tuberculosis before the clinical onset of bronchiectasis;\n\n(4) having sarcoidosis of the lung before the clinical onset of bronchiectasis;\n\n(5) having bronchial obstruction before the clinical onset of bronchiectasis, where the bronchiectasis is distal to that obstruction;\n\nNote: bronchial obstruction is defined in the Schedule 1 - Dictionary. \n\n(6) inhaling vapours, gases or fumes of a chemical agent from the specified list of chemical agents:\n\n(a) resulting in signs and symptoms of severe acute lower respiratory damage requiring medical attention within 48 hours after exposure; and\n\n(b) the persistence of respiratory symptoms and signs for at least one week after exposure,\n\nwithin the two years before the clinical onset of bronchiectasis;\n\nNote: specified list of chemical agents is defined in the Schedule 1 - Dictionary. \n\n(7) having aspiration pneumonitis within the two years before the clinical onset of bronchiectasis;\n\nNote: aspiration pneumonitis is defined in the Schedule 1 - Dictionary. \n\n(8) having gastro-oesophageal reflux disease, with erosive oesophagitis or oesophageal stricture, at the time of the clinical onset of bronchiectasis;\n\n(9) having allergic bronchopulmonary aspergillosis at the time of the clinical onset of bronchiectasis;\n\nNote: allergic bronchopulmonary aspergillosis is defined in the Schedule 1 - Dictionary. \n\n(10) undergoing solid organ or bone marrow transplantation before the clinical onset of bronchiectasis;\n\n(11) having fibrosis or fibrosing interstitial lung disease, involving the segment of the lung affected by bronchiectasis, before the clinical onset of bronchiectasis;\n\n(12) being exposed to arsenic as specified before the clinical onset of bronchiectasis;\n\nNote: being exposed to arsenic as specified is defined in the Schedule 1 - Dictionary. \n\n(13) having a disease from the specified list of connective tissue diseases at the time of the clinical onset of bronchiectasis;\n\nNote: specified list of connective tissue diseases is defined in the Schedule 1 - Dictionary. \n\n(14) having inflammatory bowel disease at the time of the clinical onset of bronchiectasis;\n\n(15) having an episode of acute viral or bacterial lower respiratory tract infection requiring medical treatment, within the six months before the clinical worsening of bronchiectasis;\n\n(16) having pertussis of sufficient severity to require hospitalisation, within the five years before the clinical worsening of bronchiectasis;\n\n(17) having pulmonary tuberculosis or non-tuberculous mycobacterial infection of the lung before the clinical worsening of bronchiectasis;\n\n(18) having sarcoidosis of the lung before the clinical worsening of bronchiectasis;\n\n(19) having bronchial obstruction before the clinical worsening of bronchiectasis, where the bronchiectasis is distal to that obstruction;\n\nNote: bronchial obstruction is defined in the Schedule 1 - Dictionary. \n\n(20) inhaling vapours, gases or fumes of a chemical agent from the specified list of chemical agents:\n\n(a) resulting in signs and symptoms of severe acute lower respiratory damage requiring medical attention within 48 hours after exposure; and\n\n(b) the persistence of respiratory symptoms and signs for at least one week after exposure,\n\nwithin the two years before the clinical worsening of bronchiectasis;\n\nNote: specified list of chemical agents is defined in the Schedule 1 - Dictionary. \n\n(21) having aspiration pneumonitis within the two years before the clinical worsening of bronchiectasis;\n\nNote: aspiration pneumonitis is defined in the Schedule 1 - Dictionary. \n\n(22) having gastro-oesophageal reflux disease, with erosive oesophagitis or oesophageal stricture, at the time of the clinical worsening of bronchiectasis;\n\n(23) having allergic bronchopulmonary aspergillosis at the time of the clinical worsening of bronchiectasis;\n\nNote: allergic bronchopulmonary aspergillosis is defined in the Schedule 1 - Dictionary. \n\n(24) undergoing solid organ or bone marrow transplantation before the clinical worsening of bronchiectasis;\n\n(25) having fibrosis or fibrosing interstitial lung disease, involving the segment of the lung affected by bronchiectasis, before the clinical worsening of bronchiectasis;\n\n(26) being exposed to arsenic as specified before the clinical worsening of bronchiectasis;\n\nNote: being exposed to arsenic as specified is defined in the Schedule 1 - Dictionary. \n\n(27) having a disease from the specified list of connective tissue diseases at the time of the clinical worsening of bronchiectasis;\n\nNote: specified list of connective tissue diseases is defined in the Schedule 1 - Dictionary. \n\n(28) having inflammatory bowel disease at the time of the clinical worsening of bronchiectasis;\n\n(29) inability to obtain appropriate clinical management for bronchiectasis.\n\n10 Relationship to service\n\n(1) The existence in a person of any factor referred to in section 9, must be related to the relevant service rendered by the person.\n\n(2) The factors set out in subsections 9(15) to 9(29) apply only to material contribution to, or aggravation of, bronchiectasis where the person's bronchiectasis was suffered or contracted before or during (but did not arise out of) the person's relevant service.\n\n11 Factors referring to an injury or disease covered by another Statement of Principles\n\nIn this Statement of Principles:\n\n(1) if a factor referred to in section 9 applies in relation to a person; and\n\n(2) that factor refers to an injury or disease in respect of which a Statement of Principles has been determined under subsection 196B(3) of the VEA;\n\nthen the factors in that Statement of Principles apply in accordance with the terms of that Statement of Principles as in force from time to time.\n\n \n\n \n\nSchedule 1 - Dictionary \n\nNote: See Section 6\n\n1 Definitions\n\nIn this instrument:\n\n allergic bronchopulmonary aspergillosis means infection of the bronchi and lungs by species of Aspergillus accompanied by wheeze, often with expectoration of yellow or brown bronchial plugs composed of eosinophils and fungal hyphae.\n\n aspiration pneumonitis means inflammation of the lungs with clinical or radiological evidence of consolidation due to the deposition into the respiratory tract of a substance or material from the upper aerodigestive tract.\n\nNote: Examples of a substance or material that may be deposited from the upper aerodigestive tract include food particles, oral secretions or gastric contents.\n\n being exposed to arsenic as specified means:\n\n(a) consuming drinking water with an average arsenic concentration of at least 50 micrograms per litre for a cumulative period of at least ten years; or\n\n(b) having clinical evidence of excessive chronic arsenic exposure.\n\n bronchial obstruction means partial or complete blockage of the lumen of a bronchus.\n\nNote: Examples of a cause of bronchial obstruction include an inhaled foreign body, broncholith or neoplasm, extrinsic narrowing due to enlarged lymph nodes, twisting or displacement of the airways after a lobar resection, or middle lobe syndrome.\n\n bronchiectasis—see subsection 7(2).\n\n MRCA means the Military Rehabilitation and Compensation Act 2004.\n\n relevant service means:\n\n(a) eligible war service (other than operational service) under the VEA;\n\n(b) defence service (other than hazardous service and British nuclear test defence service) under the VEA; or\n\n(c) peacetime service under the MRCA.\n\nNote: MRCA and VEA are also defined in the Schedule 1 - Dictionary.\n\n specified list of chemical agents means:\n\n(a) ammonia;\n\n(b) oxides of nitrogen;\n\n(c) oxides of sulphur;\n\n(d) paraquat;\n\n(e) smoke from fires; or\n\n(f) sulphur mustard (mustard gas).\n\n\n\n\n specified list of connective tissue diseases means:\n\n(a) ankylosing spondylitis;\n\n(b) rheumatoid arthritis;\n\n(c) Sjogren's syndrome;\n\n(d) systemic lupus erythematosus; or\n\n(e) systemic sclerosis.\n\n terminal event means the proximate or ultimate cause of death and includes the following:\n\n(a) pneumonia;\n\n(b) respiratory failure;\n\n(c) cardiac arrest;\n\n(d) circulatory failure; or\n\n(e) cessation of brain function.\n\n VEA means the Veterans' Entitlements Act 1986.\n\n \n\n \n","sortOrder":0}],"analysis":{"flash_summary":{"complexity_score":6,"scope_assessment":{"changed":true,"description":"The instrument expressly revokes the 2009 Statement (s4) and replaces it with a list-based framework that (a) excludes certain genetic/congenital causes (s7(2)(b)), (b) specifies named chemical agents and quantitative arsenic exposure criteria (Schedule), and (c) sets explicit temporal windows and separate tests for new onset versus clinical worsening (s9; s10). It therefore modifies the determinative framework used to link bronchiectasis to relevant service and narrows/clarifies the factual pathways claimants must prove (ss4,7–11; Schedule)."},"complexity_factors":["Multiple, discrete causal and aggravating factors are enumerated rather than a single open-ended test (s9) which creates many factual pathways to acceptance.","Different temporal windows for onset versus clinical worsening (e.g. 5 years, 2 years, 6 months) require precise timing evidence (s9(1)–(29)).","Defined inclusions and exclusions (e.g. excludes congenital bronchiectasis and cystic fibrosis) narrow scope and require diagnostic proof (s7(2)(b)).","Specified exposure thresholds and lists (e.g. arsenic ≥50 µg/L for ≥10 years; named chemical agents) impose quantitative/qualitative proof requirements (Schedule: 'being exposed to arsenic as specified'; 'specified list of chemical agents').","Interplay with other Statements of Principles means evidence may trigger application of alternate Statements (s11), increasing cross-referencing complexity.","Relationship-to-service and material contribution/aggravation rules limit when factors can establish service connection, creating legal distinctions claimants must address (s10(1)–(2)).","Balance of probabilities standard coupled with medical‑scientific judgment by the Repatriation Medical Authority concentrates decision-making discretion in an expert body (s8; instrument made under s196B(3) VEA).","Revocation and replacement of the 2009 Statement require comparison of prior and current tests for claim strategy and evidence gathering (s4).","Several defined medical terms require clinical interpretation (Schedule definitions: allergic bronchopulmonary aspergillosis, aspiration pneumonitis, bronchial obstruction, terminal event).","Application limited to statutory claim pathways (VEA/MRCA sections cited) restricts its operational scope to people pursuing those specific benefits (s5)."],"plain_english_summary":"This Statement of Principles (No. 31 of 2017) replaces the 2009 instrument and sets the medical, infectious and exposure factors the Repatriation Medical Authority uses to decide, on the balance of probabilities, whether bronchiectasis (or death from it) is connected to a veteran's or service member's relevant service (applies to claims under s120B VEA or s339 MRCA). \n\nIt lists specific clinical conditions, time windows, chemical exposures (including an arsenic threshold) and aggravation rules; if at least one listed factor exists and is related to relevant service, a service connection may be established — shifting determinations toward proving those factors and their service link (see ss7–11; Schedule)."},"kimi_summary":{"content_quality":"ok","complexity_score":4,"scope_assessment":{"changed":false,"description":"This instrument maintains the established scope of Repatriation Medical Authority Statements of Principles. It updates the 2009 version with revised medical factors but does not expand beyond the traditional purpose: establishing causal connections between specific diseases and military service for compensation purposes. The structure (onset factors vs. worsening factors) and the incorporation of external Statements of Principles are standard features of this legislative scheme."},"complexity_factors":["29 distinct factual factors with specific temporal requirements (e.g., 'within five years before', 'at the time of', 'before')","12 defined terms in Schedule 1, several with nested sub-definitions (e.g., 'being exposed to arsenic as specified' has two alternative pathways)","Cross-referencing mechanism in section 11 that incorporates other Statements of Principles by reference","Dual application framework: factors 1-14 for clinical onset vs factors 15-29 for clinical worsening, with different temporal windows","Specific chemical and disease lists that require external medical knowledge to apply (six chemical agents, five connective tissue diseases)","Exclusion clauses in the definition of bronchiectasis that require ruling out congenital and genetic causes"],"plain_english_summary":"This Statement of Principles updates the 2009 guidance on when Australian veterans and ADF members can claim compensation for acquired bronchiectasis under the Veterans' Entitlements Act 1986 and the Military Rehabilitation and Compensation Act 2004. It sets a medical-legal test — on the balance of probabilities — requiring evidence that at least one listed medical factor existed and was related to service, and excludes congenital or certain genetic causes. Two different causal tests apply depending on whether service caused the condition or worsened it."},"flash_summary_failed":{"failed":true,"reason":"A positive credit balance is required for all requests, including BYOK, so fallback providers remain available. Add credits at https://vercel.com/d?to=%2F%5Bteam%5D%2F%7E%2Fai%3Fmodal%3Dtop-up to continue.","source":"analysis-cron"}},"importantCases":[],"_links":{"self":"/api/acts/statement-of-principles-concerning-bronchiectasis-balance-of-probabilities-no-31-of-2017","history":"/api/acts/statement-of-principles-concerning-bronchiectasis-balance-of-probabilities-no-31-of-2017/history","analysis":"/api/acts/statement-of-principles-concerning-bronchiectasis-balance-of-probabilities-no-31-of-2017/analysis","conflicts":"/api/acts/statement-of-principles-concerning-bronchiectasis-balance-of-probabilities-no-31-of-2017/conflicts","importantCases":"/api/acts/statement-of-principles-concerning-bronchiectasis-balance-of-probabilities-no-31-of-2017/important-cases","documents":"/api/acts/statement-of-principles-concerning-bronchiectasis-balance-of-probabilities-no-31-of-2017/documents"}}